Ureas of 5-aminopyrazole and 2-aminothiazole inhibit growth of gram-positive bacteria

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 24, 2003, Pages 4463-4466

  Kane Jr , John L ^a   Hirth, Bradford H ^a   Liang, Beirong ^a   Gourlie, Brian B ^a   Nahill, Sharon ^a   Barsomian, Gary ^a  

^a GENZYME CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINOTHIAZOLE DERIVATIVE; 5 AMINOPYRAZOLE; ANTIINFECTIVE AGENT; PYRAZOLE DERIVATIVE; PYRAZOLE UREA; THIAZOLE UREA; UNCLASSIFIED DRUG; UREA DERIVATIVE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; CONCENTRATION RESPONSE; DRUG DETERMINATION; DRUG SCREENING; DRUG SYNTHESIS; GRAM POSITIVE BACTERIUM; IN VIVO STUDY; NONHUMAN; STAPHYLOCOCCUS AUREUS; STRUCTURE ACTIVITY RELATION;

POSIBACTERIA; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

EID: 0344495989     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2003.09.013     Document Type: Article

References (17)

1. Bronson J.J., Barrett J.F. Annu. Rep. Med. Chem. 36:2001;89.
2. Dumas J., Hatoum-Mokdad H., Sibley R., Riedl B., Scott W.J., Monahan M.K., Lowinger T.B., Brennan C., Natero R., Turner T., Johnson J.S., Schoenleber R., Bhargava A., Wilhelm S.M., Housley T.J., Ranges G.E., Shrikhande A. Bioorg. Med. Chem. Lett. 10:2000;2051.
3. Regan, J. R.; Cirillo, P. F.; Hickey, E. R.; Moss, N.; Cywin C. L.; Pargellis, C.; Gilmore, T. A. PCT Int. Appl. WO 9923091, 1999; Chem. Abstr. 1999, 130, 325145.
4. Creswell, M. W.; White, A. D. U.S. Patent 5,162,360, 1993; Chem. Abstr. 1993, 118, 147556.
5. Liebig H., Pfetzing H., Grafe A. Arzneim.-Forsch. 24:1974;887.
6. Baldwin, J. J.; McDonald, E.; Moriarty, K. J.; Sarko, C. R.; Machinaga, N.; Nakayama, A.; Chiba, J.; Iimura, S.; Yoneda, Y. PCT Int. Appl. WO 0100206, 2001; Chem. Abstr. 2001, 134, 86149.
7. Pevarello, P.; Amici, R.; Traquandi, G.; Villa, M.; Vulpetti, A.; Isacchi, A. PCT Int. Appl. WO 0026203, 2000; Chem. Abstr. 2000, 132, 334455.
8. Sutoris V., Konecny V., Foltinova P., Perjessy A., Kuchar E. Chem. Zvesti. 29:1975;552.
9. Yabuuchi T., Hisaki M., Kimura R. Chem. Pharm. Bull. 23:1975;659.
10. Pelosi, J. S. S.; Alaimo, R. J. U.S. Patent 4,028,374, 1977; Chem. Abstr. 1977, 87, 117849.
11. Hof H., Zak O., Schweizer E., Denzler A. J. Antimic. Chemother. 14:1984;31.
12. Thavonekham B. Synthesis. 1997;1189.
13. Joshi K.C., Pathak V.N., Garg U. J. Heterocyclic Chem. 16:1979;1141.
14. Wiley, R. H.; England, D. C.; Behr, L. C. In Organic Reactions; Adams, R., Ed.; Wiley & Sons: New York, 1951; p 367.
15. 50 determinations, the method was modified to allow the rapid growth of organisms. The inoculum suspensions were adjusted to 0.1 McFarland standard and then diluted 2-fold into the wells containing TB broth and the compounds. After 3-5 h incubation at 37 °C, the turbidity was measured at 550 nm and inhibitory activity was defined as the concentration of antimicrobial agent that inhibits 50% growth of the organism in the microdilution wells.
16. 7 CFU/mouse) of methicillin-resistant S. aureus (ATCC 33591) in brain-heart infusion broth containing 5% mucin. Compounds were suspended in a vehicle containing 1% cremophore RL (Sigma) in normal saline and were administered subcutaneously in a volume of 0.4 mL per mouse either 1 h prior to bacterial inoculation or 1 and 5 h post-inoculation. Animals receiving two doses of drug were injected subcutaneously in the hindquarter 1 h post-inoculation and in the neck area 5 h post-inoculation. Deaths occurring during the subsequent 4 days were recorded. Mortality and % survival endpoints were calculated.
17. Moriguchi I., Hirono S., Liu Q., Nakagome I., Matsushita Y. Chem. Pharm. Bull. 40:1992;127.